Quick Answer
Biofrontera Inc. reported Total Revenue of $41.71 million for the year ending 2025.
- Biofrontera Inc. showed an increase of +11.7% in Total Revenue from 2024 to 2025.
- This data is from Biofrontera Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $3.25 million | Q1 2021: $4.74 million | Q2 2021: $5.86 million | Q3 2021: $4.33 million | Q1 2022: $9.75 million | Q2 2022: $4.46 million | Q3 2022: $4.32 million | Q1 2023: $8.73 million | Q2 2023: $5.85 million | Q3 2023: $8.90 million | Q1 2024: $7.91 million | Q2 2024: $7.84 million | Q3 2024: $9.01 million | Q1 2025: $8.59 million | Q2 2025: $9.03 million | Q3 2025: $6.99 million.
- Over the full 6 years of available data (2020 to 2025), Biofrontera Inc.'s Total Revenue has grown by 121.3%.
- Historical annual values: Fiscal year 2025: $41.71 million | Fiscal year 2024: $37.32 million | Fiscal year 2023: $34.07 million | Fiscal year 2022: $28.67 million | Fiscal year 2021: $24.10 million | Fiscal year 2020: $18.85 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: